Why the study?
What are the patterns and persistence of anticoagulant use in the treatment of VTE in South Korea?
Observational
What are the patterns and persistence of anticoagulant use in the treatment of VTE in South Korea?
The study aims to describe the patterns and persistence of anticoagulant use for the treatment of venous thromboembolism in South Korea.
Answers are grounded in this paper and cite their sources.
Real-world VTE anticoagulant patterns in South Korea lack published data; leaves open need for dedicated cohort analyses.
When used in fixed doses for the treatment of venous thromboembolism (VTE) in patients with or without cancer, direct oral anticoagulants (DOACs) have improved risk–benefit profiles compared with vitamin K antagonists (VKAs), and have better convenience than parenteral anticoagulants such as low-molecular-weight heparins (LMWHs).[1] [2] The DOACs, which include rivaroxaban, edoxaban, dabigatran, and apixaban, have been approved for the treatment of VTE in various countries since 2011, and current guidelines prefer DOACs over VKAs for the treatment of VTE in patients without cancer, and recommend DOACs as acceptable alternatives to LMWHs in patients with cancer-associated VTE.
No takes yet. Share an insight, caveat, or question.
Germini et al. (2023) conducted an observational in Venous Thromboembolism. Anticoagulant was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: